GlassScriptPhysician profile
Hector R Corzo
NPI 1831272046
$9,293.92
in general payments reported to CMS, 2019-2025
27 companies · $1,536 in 2025
The $1,536 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,389 · 2020: $917 · 2021: $977 · 2022: $1,942 · 2023: $1,703 · 2024: $830 · 2025: $1,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,069.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,708.39 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $1,306.34 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,177.94 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $976.20 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $688.37 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $639.84 | 2019-2025 | Austedo Xr, Austedo, Uzedy |
| Alkermes, INC. | $633.42 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $400.95 | 2019-2023 | Invega Sustenna, Invega Trinza, Spravato |
| Indivior INC. | $275.81 | 2019-2023 | Perseris |
| Allergan, INC. | $247.12 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $164.86 | 2019-2025 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $145.30 | 2022-2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $122.64 | 2022 | |
| Noven Therapeutics, LLC | $101.75 | 2024-2025 | Xelstrym, Secuado |
| Lundbeck LLC | $101.68 | 2019-2025 | Rexulti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $85.95 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $83.08 | 2023-2024 | Auvelity |
| Supernus Pharmaceuticals, INC. | $68.20 | 2021-2025 | Qelbree |
| Harmony Biosciences LLC | $60.29 | 2020-2023 | Wakix |
| Eisai INC. | $56.93 | 2020-2021 | |
| Bausch Health US, LLC | $53.39 | 2019-2023 | Aplenzin |
| Ironshore Pharmaceuticals INC. | $44.20 | 2019 | |
| Orexo US, INC. | $44.12 | 2019 | |
| Almatica Pharma LLC | $43.22 | 2022-2023 | Gralise |
| Adlon Therapeutics L.P. | $23.80 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.65 | 2019 | |
| Merck Sharp & Dohme LLC | $16.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Corzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.